Ignite Creation Date:
2025-12-25 @ 12:08 AM
Ignite Modification Date:
2026-01-02 @ 12:26 PM
Study NCT ID:
NCT05164458
Status:
RECRUITING
Last Update Posted:
2023-12-28
First Post:
2021-11-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CIBI389A101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None